{"id":"part-1-double-blind-placebo-controlled","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by increasing the levels of serotonin in the brain, which helps to improve mood and reduce symptoms of depression.","oneSentence":"This drug is a selective serotonin reuptake inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:46.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT07495813","phase":"PHASE1","title":"A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Stable Coronary Artery Disease, Healthy Volunteers","enrollment":196},{"nctId":"NCT06858579","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)","status":"RECRUITING","sponsor":"Dianthus Therapeutics","startDate":"2025-02-10","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":480},{"nctId":"NCT06714253","phase":"PHASE1, PHASE2","title":"Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1","status":"RECRUITING","sponsor":"RiboX Therapeutics Ltd.","startDate":"2025-03-05","conditions":"Radiation-Induced Xerostomia and Hyposalivation","enrollment":42},{"nctId":"NCT04849728","phase":"PHASE3","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventiva Pharma","startDate":"2021-08-19","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":1000},{"nctId":"NCT04251533","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-08","conditions":"Triple Negative Breast Neoplasms","enrollment":137},{"nctId":"NCT07022119","phase":"PHASE1","title":"A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-06-12","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":32},{"nctId":"NCT07050316","phase":"PHASE1","title":"Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects","status":"COMPLETED","sponsor":"Ceres Brain Therapeutics","startDate":"2025-03-14","conditions":"Neurologic Diseases, General","enrollment":48},{"nctId":"NCT07493031","phase":"PHASE1","title":"A PhaseⅠ Study of HW252001 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","startDate":"2026-03-31","conditions":"IPF","enrollment":98},{"nctId":"NCT06637371","phase":"PHASE1","title":"A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-10-16","conditions":"Asthma","enrollment":124},{"nctId":"NCT06788756","phase":"PHASE2, PHASE3","title":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML","status":"RECRUITING","sponsor":"Moleculin Biotech, Inc.","startDate":"2025-03-12","conditions":"Acute Myeloid Leukaemia (AML)","enrollment":312},{"nctId":"NCT07489599","phase":"PHASE1","title":"A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)","enrollment":68},{"nctId":"NCT06890598","phase":"PHASE3","title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":700},{"nctId":"NCT07412691","phase":"PHASE1","title":"A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-03-19","conditions":"Skin Diseases","enrollment":98},{"nctId":"NCT07012395","phase":"PHASE2","title":"A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Spyre Therapeutics, Inc.","startDate":"2025-05-27","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis","enrollment":645},{"nctId":"NCT07207954","phase":"PHASE1","title":"Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Lifordi Immunotherapeutics, Inc.","startDate":"2025-10-06","conditions":"Rheumatoid Arthritis","enrollment":176},{"nctId":"NCT05059262","phase":"PHASE3","title":"Study of Vimseltinib for Tenosynovial Giant Cell Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2021-10-14","conditions":"Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath","enrollment":123},{"nctId":"NCT05488340","phase":"PHASE2","title":"A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)","status":"RECRUITING","sponsor":"Locus Biosciences","startDate":"2022-07-13","conditions":"Urinary Tract Infections","enrollment":318},{"nctId":"NCT06226883","phase":"PHASE2","title":"A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)","startDate":"2024-07-18","conditions":"Inflammatory Bowel Diseases, Crohn's Disease","enrollment":385},{"nctId":"NCT07245368","phase":"PHASE1, PHASE2","title":"Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma","status":"RECRUITING","sponsor":"Prana Therapies Inc","startDate":"2025-11-04","conditions":"Mild to Moderate Asthma","enrollment":96},{"nctId":"NCT05268289","phase":"PHASE2","title":"Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-10","conditions":"Lupus Nephritis","enrollment":240},{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":920},{"nctId":"NCT07169318","phase":"PHASE1","title":"First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-16","conditions":"Influenza","enrollment":78},{"nctId":"NCT07267026","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and PK of SK-09","status":"RECRUITING","sponsor":"Consun Pharmaceutical Group","startDate":"2025-12-08","conditions":"FSGS, MCD","enrollment":72},{"nctId":"NCT07235163","phase":"PHASE1","title":"A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-04-13","conditions":"Healthy","enrollment":100},{"nctId":"NCT05480228","phase":"PHASE2","title":"EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA","status":"COMPLETED","sponsor":"James P. Rathmell, MD","startDate":"2022-09-21","conditions":"Painful Diabetic Neuropathy","enrollment":127},{"nctId":"NCT07366034","phase":"PHASE3","title":"A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-07-27","conditions":"Fibrosing Interstitial Lung Disease","enrollment":35},{"nctId":"NCT04639050","phase":"PHASE1, PHASE2","title":"Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-15","conditions":"Alzheimers Disease","enrollment":241},{"nctId":"NCT06421636","phase":"PHASE2","title":"A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-30","conditions":"Non-Transfusion Dependent Beta-Thalassemia (NTDT)","enrollment":95},{"nctId":"NCT07310901","phase":"PHASE1","title":"A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity","status":"RECRUITING","sponsor":"Corbus Pharmaceuticals Inc.","startDate":"2025-12-04","conditions":"Obese But Otherwise Healthy Participants","enrollment":252},{"nctId":"NCT06531824","phase":"PHASE3","title":"EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-08-13","conditions":"Kidney Disease, Chronic","enrollment":11000},{"nctId":"NCT07024641","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"GigaGen, Inc.","startDate":"2024-11-13","conditions":"Hepatitis B Virus Infection","enrollment":48},{"nctId":"NCT06137742","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-11-17","conditions":"Pulmonary Arterial Hypertension","enrollment":96},{"nctId":"NCT06481306","phase":"PHASE1, PHASE2","title":"A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-07-17","conditions":"Anemia, Sickle Cell, Healthy Volunteers","enrollment":184},{"nctId":"NCT06836609","phase":"PHASE1","title":"A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-04-28","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis","enrollment":132},{"nctId":"NCT03100149","phase":"PHASE2","title":"A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-06-27","conditions":"Parkinson's Disease","enrollment":316},{"nctId":"NCT04512235","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-11-03","conditions":"AL Amyloidosis","enrollment":281},{"nctId":"NCT06252220","phase":"PHASE1","title":"First in Human Study in Subjects With Obesity, But Otherwise Healthy","status":"RECRUITING","sponsor":"NeuroBo Pharmaceuticals Inc.","startDate":"2024-03-25","conditions":"Obesity","enrollment":139},{"nctId":"NCT04504825","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-08-25","conditions":"AL Amyloidosis","enrollment":125},{"nctId":"NCT06602453","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2025-01-17","conditions":"Acute Kidney Injury","enrollment":67},{"nctId":"NCT06784349","phase":"PHASE1","title":"ALN-APOC3 in Adult Participants With Dyslipidemia","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-01-27","conditions":"Dyslipidemia","enrollment":32},{"nctId":"NCT06953583","phase":"PHASE3","title":"A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)","status":"RECRUITING","sponsor":"Biogen","startDate":"2025-06-09","conditions":"Friedreich Ataxia","enrollment":255},{"nctId":"NCT05115110","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-02","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":259},{"nctId":"NCT07470177","phase":"PHASE1","title":"A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2026-03-27","conditions":"ADPKD (Autosomal Dominant Polycystic Kidney Disease)","enrollment":24},{"nctId":"NCT06990867","phase":"PHASE2, PHASE3","title":"Optimizing Reperfusion to Improve Outcomes and Neurologic Function","status":"RECRUITING","sponsor":"Corxel Pharmaceuticals","startDate":"2025-05-15","conditions":"Acute Ischemic Stroke","enrollment":740},{"nctId":"NCT06559306","phase":"PHASE3","title":"Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-07-25","conditions":"Depressive Disorder, Major","enrollment":752},{"nctId":"NCT07471932","phase":"PHASE1","title":"A Study of LAD106 in Healthy Adult Participants","status":"RECRUITING","sponsor":"Almirall, S.A.","startDate":"2026-02-17","conditions":"Healthy Volunteers","enrollment":93},{"nctId":"NCT06941844","phase":"PHASE3","title":"A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","startDate":"2025-04-14","conditions":"Major Depressive Disorder","enrollment":149},{"nctId":"NCT06809595","phase":"PHASE3","title":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","status":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","startDate":"2025-01-29","conditions":"Generalized Anxiety Disorder","enrollment":250},{"nctId":"NCT07198386","phase":"PHASE2","title":"Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)","status":"RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2025-09-30","conditions":"NASH","enrollment":120},{"nctId":"NCT06782373","phase":"PHASE2","title":"A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-05-28","conditions":"VEXAS, VEXAS Syndrome","enrollment":78},{"nctId":"NCT05027269","phase":"PHASE1, PHASE2","title":"Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients","status":"COMPLETED","sponsor":"Avidity Biosciences, Inc.","startDate":"2021-10-28","conditions":"DM1, Myotonic Dystrophy 1, Myotonic Dystrophy","enrollment":39},{"nctId":"NCT07463846","phase":"PHASE1, PHASE2","title":"A Study to Evaluate ALN-2232 in Participants With Obesity","status":"RECRUITING","sponsor":"Alnylam Pharmaceuticals","startDate":"2026-03-02","conditions":"Obesity","enrollment":156},{"nctId":"NCT07262281","phase":"PHASE1","title":"Evaluation of the Safety, Tolerability and Pharmacokinetics of HY6725 in Healthy Adult Participants","status":"RECRUITING","sponsor":"Newsoara Biopharma Co., Ltd.","startDate":"2026-02-06","conditions":"Healthy","enrollment":74},{"nctId":"NCT07463196","phase":"PHASE1","title":"A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants","status":"RECRUITING","sponsor":"AC Immune SA","startDate":"2026-01-28","conditions":"Healthy Participants","enrollment":78},{"nctId":"NCT06961708","phase":"PHASE1","title":"A Study of Fosmanogepix in Healthy Adult Chinese Subjects","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2025-04-14","conditions":"Healthy","enrollment":54},{"nctId":"NCT07281703","phase":"PHASE1","title":"Evaluation of the Safety, Tolerability and Pharmacokinetics of HY8931 in Healthy Adult Participants","status":"RECRUITING","sponsor":"Newsoara Biopharma Co., Ltd.","startDate":"2026-01-14","conditions":"Healthy","enrollment":60},{"nctId":"NCT05574010","phase":"PHASE1, PHASE2","title":"A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)","status":"TERMINATED","sponsor":"Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA","startDate":"2022-11-15","conditions":"Celiac Disease","enrollment":128},{"nctId":"NCT04910685","phase":"PHASE2, PHASE3","title":"(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis","status":"RECRUITING","sponsor":"Blueprint Medicines Corporation","startDate":"2021-11-30","conditions":"Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis","enrollment":534},{"nctId":"NCT06290934","phase":"PHASE2","title":"Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-03-27","conditions":"Ulcerative Colitis","enrollment":228},{"nctId":"NCT06834932","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-12-06","conditions":"Dyslipidaemia","enrollment":360},{"nctId":"NCT06144710","phase":"PHASE1","title":"SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","startDate":"2023-11-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":48},{"nctId":"NCT06649110","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Healthy Volunteers, Pulmonary Arterial Hypertension","enrollment":232},{"nctId":"NCT07304843","phase":"PHASE1, PHASE2","title":"A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction","status":"RECRUITING","sponsor":"Umecrine Cognition AB","startDate":"2023-04-14","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":84},{"nctId":"NCT07250802","phase":"PHASE3","title":"A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-12-04","conditions":"Plaque Psoriasis","enrollment":110},{"nctId":"NCT06971731","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-10-20","conditions":"Phenylketonuria","enrollment":120},{"nctId":"NCT06619990","phase":"PHASE1, PHASE2","title":"Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis","status":"RECRUITING","sponsor":"Xencor, Inc.","startDate":"2024-10-10","conditions":"Ulcerative Colitis (UC)","enrollment":270},{"nctId":"NCT05503264","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-09-27","conditions":"NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis","enrollment":152},{"nctId":"NCT07456800","phase":"PHASE1","title":"PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects","status":"COMPLETED","sponsor":"PureTech","startDate":"2021-07-12","conditions":"Pharmacokinetic Analysis","enrollment":116},{"nctId":"NCT06166056","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-11-29","conditions":"Bronchiectasis","enrollment":45},{"nctId":"NCT06864104","phase":"PHASE2","title":"A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kardigan, Inc.","startDate":"2025-04-10","conditions":"Hypertension","enrollment":206},{"nctId":"NCT06787586","phase":"PHASE1","title":"Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Attovia Therapeutics Inc","startDate":"2025-01-14","conditions":"Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema","enrollment":108},{"nctId":"NCT05835752","phase":"PHASE1","title":"The Safety, Tolerability and Pharmacokinetic Study of RAY1225","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-05-18","conditions":"Obese, Healthy","enrollment":68},{"nctId":"NCT07229911","phase":"PHASE1","title":"A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-07","conditions":"Healthy Volunteers, Primary Sclerosing Cholangitis","enrollment":134},{"nctId":"NCT07221240","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis","status":"RECRUITING","sponsor":"PRG Science & Technology Co., Ltd.","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis","enrollment":48},{"nctId":"NCT02362594","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-16","conditions":"Melanoma","enrollment":1019},{"nctId":"NCT07389044","phase":"PHASE1","title":"A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B","status":"RECRUITING","sponsor":"IntegerBio","startDate":"2026-02-20","conditions":"Chronic Hepatitis B Virus Infection","enrollment":90},{"nctId":"NCT07449572","phase":"PHASE1","title":"Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS","status":"NOT_YET_RECRUITING","sponsor":"HTIC, Inc","startDate":"2026-03","conditions":"ARDS (Acute Respiratory Distress Syndrome)","enrollment":24},{"nctId":"NCT05186753","phase":"PHASE2","title":"(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cogent Biosciences, Inc.","startDate":"2022-06-27","conditions":"SSM, Mastocytosis, Indolent, Mastocytosis, Systemic","enrollment":237},{"nctId":"NCT07420283","phase":"PHASE2","title":"A Study of Brenipatide in Participants With Opioid Use Disorder","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-13","conditions":"Opioid Use Disorder","enrollment":465},{"nctId":"NCT05407324","phase":"PHASE2","title":"Dazucorilant in Patients With Amyotrophic Lateral Sclerosis","status":"RECRUITING","sponsor":"Corcept Therapeutics","startDate":"2022-11-15","conditions":"Amyotrophic Lateral Sclerosis","enrollment":279},{"nctId":"NCT05050136","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis","status":"RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2021-09-22","conditions":"Primary Biliary Cholangitis, PBC","enrollment":260},{"nctId":"NCT07335913","phase":"PHASE1","title":"Phase 1 Study of SBS-147 in Healthy Adults","status":"RECRUITING","sponsor":"Sparian Biosciences, Inc","startDate":"2026-01-08","conditions":"Pain Acute, Pain","enrollment":80},{"nctId":"NCT06780254","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of Single- and Multiple-Ascending Doses of MH-001 in Healthy Volunteers","status":"COMPLETED","sponsor":"Vespina Lifesciences Inc.","startDate":"2024-09-09","conditions":"Healthy","enrollment":58},{"nctId":"NCT07160634","phase":"PHASE3","title":"A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)","status":"RECRUITING","sponsor":"Solid Biosciences Inc.","startDate":"2025-10-22","conditions":"Duchenne Muscular Dystrophy","enrollment":80},{"nctId":"NCT07223216","phase":"PHASE1","title":"Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants","status":"RECRUITING","sponsor":"Biomea Fusion Inc.","startDate":"2025-10-23","conditions":"Obesity","enrollment":80},{"nctId":"NCT05691361","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ADARx Pharmaceuticals, Inc.","startDate":"2022-12-14","conditions":"Hereditary Angioedema","enrollment":53},{"nctId":"NCT04809818","phase":"PHASE1","title":"A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects","status":"COMPLETED","sponsor":"Lumosa Therapeutics Co., Ltd.","startDate":"2021-03-21","conditions":"Acute Ischemic Stroke","enrollment":65},{"nctId":"NCT07220811","phase":"PHASE2","title":"Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy","status":"RECRUITING","sponsor":"RAPT Therapeutics, Inc.","startDate":"2025-10-22","conditions":"Ig-E Mediated Food Allergy","enrollment":100},{"nctId":"NCT06895343","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2025-04-03","conditions":"Healthy Volunteer","enrollment":100},{"nctId":"NCT06306014","phase":"PHASE1, PHASE2","title":"Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-05-07","conditions":"Clostridioides Difficile Infection, Recurrent Infection","enrollment":56},{"nctId":"NCT07437105","phase":"PHASE1","title":"Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2026-02-23","conditions":"Cystic Fibrosis","enrollment":128},{"nctId":"NCT07035769","phase":"PHASE1","title":"A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-06-18","conditions":"Healthy Participants","enrollment":88},{"nctId":"NCT06741228","phase":"PHASE3","title":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)","status":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","startDate":"2024-12-11","conditions":"Generalized Anxiety Disorder","enrollment":200},{"nctId":"NCT03016819","phase":"PHASE3","title":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","status":"RECRUITING","sponsor":"Advenchen Laboratories, LLC","startDate":"2017-08-15","conditions":"Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma","enrollment":325},{"nctId":"NCT07266805","phase":"PHASE3","title":"Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency","status":"RECRUITING","sponsor":"Pharvaris Netherlands B.V.","startDate":"2025-10-16","conditions":"Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)","enrollment":32},{"nctId":"NCT05469737","phase":"PHASE2, PHASE3","title":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-12-14","conditions":"Myelodysplastic Syndromes","enrollment":230},{"nctId":"NCT03631199","phase":"PHASE3","title":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer","enrollment":673},{"nctId":"NCT07423299","phase":"PHASE1","title":"A First-in-Human Single and Multiple Ascending Dose Study of MT-251","status":"RECRUITING","sponsor":"Mirador Therapeutics, Inc.","startDate":"2026-01-23","conditions":"Healthy Volunteers","enrollment":70},{"nctId":"NCT05549323","phase":"PHASE1","title":"A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-11-07","conditions":"Ulcerative Colitis","enrollment":44},{"nctId":"NCT07430397","phase":"PHASE1","title":"A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation","status":"RECRUITING","sponsor":"City Therapeutics","startDate":"2026-01-22","conditions":"Factor V Leiden, Prothrombin G20210A","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1376,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PART 1: Double-blind Placebo-controlled","genericName":"PART 1: Double-blind Placebo-controlled","companyName":"Sun Pharmaceutical Industries Limited","companyId":"sun-pharmaceutical-industries-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug is a selective serotonin reuptake inhibitor. Used for Major depressive disorder, Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}